// App-Quantinova.ai

TCT-449 : Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent versus Cobalt-Chromium Everolimus-Eluting Stent in De Novo Native Coronary Lesions: The Final 5-Year Results of the TARGET I Randomized Controlled Trial

Researchers

Presenter

  • Bo Xu

Principal Investigators

  • Changdong Guan

  • Yuejin Yang

  • Yaling Han

  • Shao-Liang Chen

  • Alexandra Lansky

  • Martin Leon

  • Runlin Gao

Medical Centers

  • Cardiovascular Institute and Fu Wai Hospital, Beijing, Beijing, China

  • Fu Wai Hospital, National Center for Cardiovascular Diseases, China, Beijing, China

  • Shenyang, Liaoning, China

  • Yale School of Medicine, New Haven, Connecticut, United States

  • Newyork Presbyterian Hospital, Newyork, New York, United States

  • Fu Wai Hospital, Beijing, Beijing, China

  • Nanjing First Hospital, Nanjing Medical University, Nanjing, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

  • Everolimus

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved